Zacks Investment Research
26 Jun 2026, 15:45 UTC · 2h ago
Ascendis Pharma (ASND) Moves 9.9% Higher: Will This Strength Last?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
26 Jun 2026, 15:45 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Ascendis Pharma (ASND) is projected to report a year-over-year quarterly earnings increase of 238.7% and revenue growth of 98.4%. — Massive projected growth in both top and bottom lines typically drives strong positive investor sentiment and price appreciation.
+0.60Gilead Sciences (GILD) has seen its consensus EPS estimate for the upcoming report drop by 13.2% over the last month to -$7.2. — Downward revisions in earnings estimates are generally viewed as a bearish signal for the stock's near-term performance.
-0.50The consensus EPS estimate for Ascendis Pharma (ASND) has been revised marginally lower over the last 30 days. — Negative estimate revisions often act as a headwind that can counteract positive price momentum.
-0.20Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
Shares soared nearly 10% due to growing investor confidence in the commercial performance of two marketed drugs.
The stock closed lower, has returned negatively over the past month, and consensus EPS estimates have been revised downward.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
2h ago
